In addition to the expected ESR1 hotspot mutations, ERBB2 and NF1 were the genes, mostly mutually exclusive, with the greatest difference in mutational frequency between pre- and post-hormonal therapy for HR + HER2− breast cancers [1]. The gene discussed is ESR1; the disease is breast carcinoma.